The only drugs that clear the dormant liver stage of malaria, and they cause haemolysis in G6PD deficiency — which is common precisely where malaria is. Testing before prescribing is genuinely routine here, which is rare.
What this drug connects to
Solid lines are connections this site curates. Dashed lines mean the two ends share a research paper — worth knowing, and not a claim that one explains the other.
These clear the dormant liver stage of malaria and both cause dose-dependent haemolysis in G6PD deficiency. Testing before prescribing is standard where they are used, which makes this one of the few places in the world where a pharmacogenetic test is genuinely routine.
CPIC Guideline for G6PD Genotype and Medication Use (Clin Pharmacol Ther 2023, PMID 36049896).
Whose work this rests on
Every guideline above was written by people. Named here because they are contributors to this page in the same sense anybody else on this site is.
Clinical pharmacology and therapeutics · 2023 · PMID 36049896
Variants MyGeneLog reports for these genes
These are the positions in your own file that carry the genes above. Not every gene in a guideline is one we report — where that is the case the gene appears above without a variant here, and the note says so.
This page is educational and contains no dosing information. Where a clinical guideline covers one of these gene-drug pairs it is written for prescribers and works through validated algorithms alongside clinical monitoring. Nothing here is a reason to start, stop, or change a medication — that conversation belongs with the clinician or pharmacist managing your treatment.